Akademik Veri Yönetim Sistemi
ENT Updates, cilt.14, sa.1, ss.5-10, 2024 (ESCI)
Background: Recently, there has been interest in the immunoregulatory and preven- tative effects of immunoglobulin A (IgA) in individuals with allergic rhinitis (AR). Topi- cal corticosteroids are one of the main treatment options for AR. The purpose of this study was to investigate the secretory IgA (sIgA) levels in the nasal fluid of healthy people and people who had received intranasal beclomethasone dipropionate (BD) and triamcinolone acetonide (TA) treatment. Methods: There were 29 newly diagnosed AR patients and 29 healthy control individu- als in the study. Group 1 (n = 13) treated with BD and group 2 (n = 16) treated with TA were included. Blood samples were collected to measure IgE levels. Nasal secretions were collected through nasal packing and evaluated by enzyme-linked immunosor- bent assay. Results: The mean nasal fluid sIgA level was 573.7 ± 192.2 μg/mL in group 1, 564.8 ± 270.8 μg/mL in group 2, and 559.7 ± 241.9 μg/mL in the control group. The dif- ference in baseline sIgA levels between groups was not statistically significant. After 1 month of nasal steroid treatment, sIgA levels in groups 1 and 2 increased significantly. Conclusion: It was found that adult AR patients who were being treated with 2 types of intranasal corticosteroids (BD and TA) have significantly higher levels of sIgA in their nasal secretions.